https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-03-20 / Rev Mal Respir 2019 Mar;36(3):415-425
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-03-20 / Rev Mal Respir 2019 Mar;36(3):415-4252019-03-20 00:00:002019-03-20 00:00:00[Vaccines for the treatment of non-small cell lung cancer]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-29 / Clin Transl Oncol 2019 Jun;21(6):721-728
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-29 / Clin Transl Oncol 2019 Jun;21(6):721-7282018-10-29 00:00:002018-10-29 00:00:00Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients‘ preference-based study (PPPS)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-09-23 / Thorac Cancer 2018 Nov;9(11):1437-1452
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-09-23 / Thorac Cancer 2018 Nov;9(11):1437-14522018-09-23 00:00:002019-02-15 08:45:47Recombinant Newcastle disease virus expressing human IFN-λ1 (rL-hIFN-λ1)-induced apoptosis of A549 cells is connected to endoplasmic reticulum stress pathways
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-01 / Am J Cancer Res 2018;8(8):1514-1527
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-01 / Am J Cancer Res 2018;8(8):1514-15272018-08-01 00:00:002018-08-01 00:00:00Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-03 / J Clin Oncol 36, 2018 (suppl; abstr 9051)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-03 / J Clin Oncol 36, 2018 (suppl; abstr 9051)2018-06-03 00:00:002018-06-03 00:00:00Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC primary analysis of phase 2, open-label, randomized, multicenter trial.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-12-21 / BMC Cancer 2017 12;17(1):884
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-12-21 / BMC Cancer 2017 12;17(1):8842017-12-21 00:00:002019-02-15 08:45:44Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-21 / Int. Immunopharmacol. 2017 Nov;52:197-202
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-21 / Int. Immunopharmacol. 2017 Nov;52:197-2022017-09-21 00:00:002019-02-15 08:45:45Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-05-03 / Clin. Cancer Res. 2017 Aug;23(16):4556-4568
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-05-03 / Clin. Cancer Res. 2017 Aug;23(16):4556-45682017-05-03 00:00:002019-02-15 08:45:43Phase I Trial of Intratumoral Injection of Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8 T-cell Infiltration
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-22 / Cancer Immunol. Immunother. 2016 09;65(9):1099-111
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-22 / Cancer Immunol. Immunother. 2016 09;65(9):1099-1112016-07-22 00:00:002019-02-15 08:45:42Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-16 / J Drug Target 2016 11;24(9):865-877
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-16 / J Drug Target 2016 11;24(9):865-8772016-06-16 00:00:002019-02-15 09:18:22Thermosensitive liposomal cisplatin in combination with local hyperthermia results in tumor growth delay and changes in tumor microenvironment in xenograft models of lung carcinoma
